Dangerous Type 2 Diabetes Drugs
More and more people in the U.S. are being diagnosed with Type 2 diabetes. The rapid increase is blamed on the obesity epidemic because Type 2 diabetes often hits those who are overweight.
For drug manufacturers, the Type 2 diabetes epidemic is an opportunity to develop and market drugs for people who have been diagnosed with the disease. At the Girardi | Keese law firm in California, our attorneys applaud the researchers and manufacturers who develop drugs that help people with Type 2 diabetes. But when a drug is rushed through the process to take advantage of market opportunities, people are often harmed for no reason other than drug company profits.
We refuse to stand by and watch when drug companies put profit over patient safety. If you have been harmed by a dangerous Type 2 diabetes drug, our lawyers have the resources and passion to help you seek justice. Call 800-401-4530or contact us online .
We Stand Against Drug Companies In Court
The trial lawyers at Girardi | Keese have the experience and knowledge to investigate and prepare complex cases for trial. We were the first law firm to file a lawsuit against Vioxx. Our attorneys know how to ask the right questions, find the right experts and develop a strong case even when faced with armies of Big Pharma lawyers.
We Fight Against Dangerous Type 2 Diabetes Drugs
Type 2 diabetes affects the way the body metabolizes sugar. The body either resists insulin or produces some but not enough insulin to maintain normal levels of glucose. Weight reduction and exercise may be able to control the problem, but patients often need the help of Type 2 diabetes drugs. But not every drug works as it should:
- Type 2 diabetes can cause pancreas problems — so can Type 2 diabetes drug Byetta.
When the drugs are on the side of the disease and not the patient, someone needs to be held accountable. At Girardi | Keese, our lawyers help people who have been harmed by Actos, Byetta and Avandia side effects.
For more information, contact us to set up an appointment.